Saba, N. F., Blumenschein, G., Guigay, J., Licitra, L., Fayette, J., Harrington, K. J., . . . Brossart, P. (2019). Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age. Oral Oncol.
Styl ChicagoSaba, Nabil F., et al. "Nivolumab Versus Investigator’s Choice in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 By Age." Oral Oncol 2019.
Citace podle MLASaba, Nabil F., et al. "Nivolumab Versus Investigator’s Choice in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 By Age." Oral Oncol 2019.